Literature DB >> 7951340

Complications of primary retroperitoneal lymph-node dissection for low-stage testicular cancer.

J Baniel1, R S Foster, R G Rowland, R Bihrle, J P Donohue.   

Abstract

The surgical complications encountered in 478 patients who underwent primary retroperitoneal lymph-node dissection for clinical stage A and B nonseminomatous testicular cancer during the period ranging from 1982 to 1992 were reviewed. There were 54 complications in 51 patients (10.6%), and there was no surgery-related mortality. There were 16 minor complications and 38 major complications. The most frequent complication encountered was superficial wound infection, and many of the major complications were related to small-bowel obstruction and atelectasis. The incidence of complications was significantly lower in patients operated on during the last 6 years of the study (1987-1992). The complication rate was lower in patients who underwent modified unilateral procedures than in those who had bilateral dissections. The ejaculation rate of patients undergoing nerve-sparing procedures was 98%. This study reinforces the conclusion that primary retroperitoneal lymph-node dissection is an operation yielding minimal morbidity and no long-standing effect.

Entities:  

Mesh:

Year:  1994        PMID: 7951340     DOI: 10.1007/BF00192272

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  19 in total

1.  Complications of retroperitoneal lymph node dissection.

Authors:  R Bihrle; J P Donohue; R S Foster
Journal:  Urol Clin North Am       Date:  1988-05       Impact factor: 2.241

2.  Complications of retroperitoneal lymphadenectomy.

Authors:  A L Sago; T P Ball; D E Novicki
Journal:  Urology       Date:  1979-03       Impact factor: 2.649

3.  Complications from staging laparotomy for Hodgkin's disease.

Authors:  R Slavin; T S Nelsen
Journal:  Natl Cancer Inst Monogr       Date:  1973-05

Review 4.  Role of adjuvant chemotherapy in patients with stage II nonseminomatous germ-cell tumors.

Authors:  R J Motzer; G J Bosl
Journal:  Urol Clin North Am       Date:  1993-02       Impact factor: 2.241

5.  Nerve-sparing retroperitoneal lymphadenectomy for testis cancer. Evolution of surgical templates for low-stage disease.

Authors:  J P Donohue
Journal:  Eur Urol       Date:  1993       Impact factor: 20.096

6.  Complications of transabdominal retroperitoneal lymphadenectomy.

Authors:  R J Babaian; R B Bracken; D E Johnson
Journal:  Urology       Date:  1981-02       Impact factor: 2.649

7.  Complications of retroperitoneal lymph node dissection.

Authors:  J P Donohue; R G Rowland
Journal:  J Urol       Date:  1981-03       Impact factor: 7.450

8.  Localization of solitary and multiple metastases in stage II nonseminomatous testis tumor as basis for a modified staging lymph node dissection in stage I.

Authors:  L Weissbach; E A Boedefeld
Journal:  J Urol       Date:  1987-07       Impact factor: 7.450

Review 9.  Surveillance versus nerve-sparing retroperitoneal lymphadenectomy in stage I nonseminomatous germ-cell tumors.

Authors:  B A Lowe
Journal:  Urol Clin North Am       Date:  1993-02       Impact factor: 2.241

10.  Primary retroperitoneal lymph node dissection in clinical stage A non-seminomatous germ cell testis cancer. Review of the Indiana University experience 1965-1989.

Authors:  J P Donohue; J A Thornhill; R S Foster; R G Rowland; R Bihrle
Journal:  Br J Urol       Date:  1993-03
View more
  3 in total

1.  Evolving patterns of care in the management of stage I non-seminomatous germ cell tumors: data from the California Cancer Registry.

Authors:  Stanley A Yap; Lindsay M Yuh; Christopher P Evans; Marc A Dall'Era; Rebecca M Wagenaar; Rosemary Cress; Primo N Lara
Journal:  World J Urol       Date:  2016-06-15       Impact factor: 4.226

Review 2.  Early-stage testis cancer.

Authors:  R S Foster
Journal:  Curr Treat Options Oncol       Date:  2001-10

3.  Stage II nonseminomatous germ-cell testicular tumors--the Indiana experience and risk-benefit analysis.

Authors:  R S Foster; R Bihrle; J S Little; R G Rowland; J P Donohue
Journal:  World J Urol       Date:  1994       Impact factor: 4.226

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.